Abstract:Objective:To explore the influence of differentiated outpatient reimbursement policies of basic medical insurance in some areas of China on the treatment level and medical expenses of adult hemophilia A patients.Methods:The outpatient reimbursement policies of hemophilia A in 5 cities(NB, XM, TJ, SY and ZZ)were systematically reviewed and compared. The basic characteristics, dosage of coagulation factors and medical expenses of hemophilia A patients in the 5 cities in 2018 were collected retrospectively to explore the influence of outpatient reimbursement policy on the treatment level and medical expenses of patients, and the differences of medical expenses between on-demand treatment and prophylaxis treatment were analyzed.Results:The reimbursement policies for hemophilia A outpatients in different regions were quite different. NB medical insurance had the best treatment, mainly reflected in the high reimbursement rate, no capping line(only urban employee medical insurance), and could be connected with major illness insurance; XM and TJ were relatively good, SY and ZZ were not ideal. The level of reimbursement of patients was also affected by their types of insurance. Adult patients of ZZ and SY were mostly covered by basic medical insurance for urban and rural residents, and their medical insurance benefits were relatively poor. In terms of treatment level, NB patients received the highest proportion of prophylaxis treatment(21 cases, 72.4%), followed by XM(8 cases, 26.7%), TJ(10 cases, 20.0%), and SY(5 cases, 10.2%), and no patients in ZZ received prophylaxis treatment. The areas with good reimbursement policy for outpatients were also accompanied by higher treatment costs, and the costs of prophylaxis treatment groups in each city were higher than those of the on-demand treatment group.Conclusions:At present, there are obvious differences in outpatient reimbursement treatment of hemophilia A patients in some areas of China. The standardization of patients receiving treatment is greatly affected by the level of medical insurance reimbursement. The improvement of reimbursement treatment will significantly improve the treatment level of patients, and also accompanied with higher medical expenses. The expenses of prophylaxis treatment group are higher than those of on-demand treatment group. It is suggested to further narrow the differences of reimbursement levels in different regions, and to improve the treatment level of patients with severe illness insurance, so as to reduce the burden of hemophilia A patients.

Application of Multiple Criteria Decision Analysis in Prophylactic Therapy on Hemophilia A in China

Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China

Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study

Treatment Status and Economic Burden of People with Hemophilia in Mainland China: A Systematic Review

A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Effect of reimbursement policy of basic medical insurance on the treatment level and cost of hemophilia A patients in China

Use of prophylaxis in patients with hemophilia and its relationship with medical expenditure in urban China

The current status and influential factors of regular prophylaxis in Chinese children with severe hemophilia A——A survey of 12 centers

Cost-effectiveness Analysis of Recombinant Factor IX Fc Fusion Protein Compared with Recombinant Factor IX for the Treatment of Moderate-Severe to Severe Hemophilia B in China.

Report on the diagnosis and treatment of hemophilia in China (Version 2024)

Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India

Evaluation of safety and inhibitor development of recombinant factor Ⅷ treatment in hemophilia A patients:a retrospective nationwide multicenter analysis in China

Analysis of the Effects of Low/intermediate Dose of Coagulation Factor Ⅷ on 30 Adult Patients with Severe Hemophilia A in a Single Center

Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study

Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study

Current status of treatment and disease burden of a cohort of hemophilia B in China

The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study

Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study

PSY12 The Prevalence and Treatment Status of Hemophilia in India, Russia, Taiwan and Turkey: A Systematic Review and Meta Analysis

Pharmacokinetic Parameter Driven Outcomes Model Predicts a Reduction in Bleeding Events Associated with BAY 81–8973 Versus Antihemophilic Factor (recombinant) Plasma/albumin-Free Method in a Chinese Healthcare Setting